Bystolic(R): a beta-blocker with benefits?
Metadata[+] Show full item record
Bystolic (nebivolol) has not demonstrated superiority to other beta-blockers for lowering blood pressure (BP), but may be associated with fewer side effects. It has been evaluated only in studies assessing the intermediate outcome of BP lowering, not patient-oriented outcomes, such as cardiovascular morbidity or mortality. Because this drug is not available in a generic formulation, Bystolic's place in hypertension therapy must be evaluated considering price and postulated advantages.
Evidence-based practice 11, no. 12 (2008): 09-10